Regina Nuccio

Regina Nuccio

Auto-generated profile, based on publicly available information

Regina Nuccio

Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RMRose B. McGee
Rose B. McGee
NONinad Oak
Ninad Oak
LHLynn Harrison
Lynn Harrison
KXKe Xu
Ke Xu
RNRegina Nuccio
Regina Nuccio
KNKim E. Nicols
Kim E. Nicols
Purpose: Clinical genomic sequencing of pediatric tumors is increasingly uncovering pathogenic variants in adult-onset cancer predisposition genes (aoCPG). Nevertheless, it remains poorly understood how often aoCPG variants are of germline origin and whether they influence tumor molecular profiles and/or clinical care. In this study, we examined the prevalence, spectrum, and impacts of aoCPG variants on tumor genomic features and patient management at our institution. Experimental Design: This is a retrospective study of 1,018 children with cancer who underwent clinical genomic sequencing of their tumors. Tumor genomic data were queried for pathogenic variants affecting 24 preselected aoCPGs. Available tumor whole-genome sequencing (WGS) data were evaluated for second hit mutations, loss of heterozygosity (LOH), DNA mutational signatures, and homologous recombination deficiency (HRD). Patients whose tumors harbored one or more pathogenic aoCPG variants underwent subsequent germline testing based on hereditary cancer evaluation and family or provider preference. Results: Thirty-three patients (3%) had tumors harboring pathogenic variants affecting one or more aoCPGs. Among 21 tumors with sufficient WGS sequencing data, six (29%) harbored a second hit or LOH affecting the remaining aoCPG allele with four of these six tumors (67%) also exhibiting a DNA mutational signature consistent with the altered aoCPG. Two additional tumors demonstrated HRD, of uncertain relation to the identified aoCPG variant. Twenty-one of 26 patients (81%) completing germline testing were positive for the aoCPG variant in the germline. All germline-positive patients were counseled regarding future cancer risks, surveillance, and risk-reducing measures. No patients had immediate cancer therapy changed due to aoCPG data. Conclusions: AoCPG variants are rare in pediatric tumors; however, many originate in the germline. Almost one third of tumor aoCPG variants examined exhibited a second hit and/or conferred an abnormal DNA mutational profile suggesting a role in tumor formation. aoCPG information aids in cancer risk prediction but is not commonly used to alter the treatment of pediatric cancers.

28 May 2025 in Journal of Genetic Counseling
Verified
Journal Article
Open access
BRBrian Reys
Brian Reys
AVAlyssa Valentine
Alyssa Valentine
VPVivian Pan
Vivian Pan
DGDelaney Gaston
Delaney Gaston
MHMardarius Harper
Mardarius Harper
RNRegina Nuccio
Regina Nuccio
Payer enrollment for genetic counselors (GCs) is fundamental to long‐term field sustainability and patient care access. Until federal recognition is obtained, enhancing Medicaid policies may help address existing GC coverage disparities. Understanding the current landscape is critical to mapping an effective strategy for future advocacy efforts. This study assessed GC provider enrollment and relevant CPT® codes across Medicaid programs in the United States via a review of open‐access Medicaid websites for 50 US states, Washington, DC, and 5 US territories in 2024. Medicaid fee status for CPT® code 96040 (GC only, 30 min) and S0265 (GC with physician supervision, 15 min code), fee schedule dates, availability of GC as a provider enrollment type, and state licensure status were abstracted. Of Medicaid provider enrollment websites for US states and DC, 21.6% (11/51) included genetic counselors; 49% (25/51) listed CPT® code 96040 and 13.7% (7/51) listed S0265 in the fee schedule with a non‐zero rate; none of the US territories listed either. Of the 34 regions with GC licensure, 32.4% (11/34) included GCs as an enrollment type in their state Medicaid provider website, while none of the 22 unlicensed regions did. This assessment highlights a gap between state licensure efforts and enrollment of GCs by state payers. Advocacy and public health policy directly targeting state Medicaid programs provide another avenue to increase coverage for GC services. A key downstream benefit of GC recognition through these efforts includes expanding access to genetic counseling services for underserved communities.

27 June 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
CHClaudia Harrison
Claudia Harrison
ABAlise K. Blake
Alise K. Blake
YSYin Su
Yin Su
LTLi Tang
Li Tang
NONinad Oak
Ninad Oak
KNKim E. Nicols
Kim E. Nicols
Purpose: Pediatric thyroid carcinoma is a rare cancer for which germline genetic factors remain incompletely understood. To gain further insight, we examined the prevalence and spectrum of pathogenic variants (PV) in cancer-predisposing genes (CPG) in a large cohort of children with thyroid carcinoma at our institution. Experimental Design: This retrospective study included 71 children who presented with thyroid carcinoma as a first (n = 52) or subsequent malignant neoplasm (n = 19) and underwent germline testing. The objectives were to determine the proportion of patients harboring PVs and correlate germline information with clinical features, tumor pathology, and outcome. Results: Eighteen patients (25%; 7 primary and 11 subsequent malignant neoplasm) harbored a PV affecting a CPG. Four of these patients had medullary thyroid carcinoma, whereas 14 had nonmedullary thyroid carcinoma. Children diagnosed with thyroid carcinoma before 11 years of age were significantly more likely to harbor PVs (P < 0.01), as were children with medullary histology tumors (P < 0.05) or a prior cancer history (P < 0.001). Both RB1-associated thyroid carcinomas occurred in children who never received prior chemotherapy or radiotherapy. Seventeen patients remain alive at a median of 3 years since diagnosis (1 month–27 years). Twelve of 18 patients with PVs were treated only with thyroidectomy, whereas six required radioactive iodine therapy or chemotherapy. One patient with multiple endocrine neoplasia type 2 expired. Conclusions: A substantial proportion of children with thyroid carcinoma harbor a CPG PV. Accordingly, genetic counseling and testing should be considered for all affected children, especially those who are young, have medullary thyroid carcinoma, or a prior cancer history.

2 September 2025
Verified
Other
Open access
CHClaudia Harrison
Claudia Harrison
ABAlise K. Blake
Alise K. Blake
YSYin Su
Yin Su
LTLi Tang
Li Tang
NONinad Oak
Ninad Oak
KNKim E. Nicols
Kim E. Nicols
Supplemental Table 2. Genes included on multigene panel tests.

2 September 2025
Verified
Other
Open access
CHClaudia Harrison
Claudia Harrison
ABAlise K. Blake
Alise K. Blake
YSYin Su
Yin Su
LTLi Tang
Li Tang
NONinad Oak
Ninad Oak
KNKim E. Nicols
Kim E. Nicols
Supplemental Table 1. Germline genetic testing completed.

2 September 2025
Verified
Other
Open access
CHClaudia Harrison
Claudia Harrison
ABAlise K. Blake
Alise K. Blake
YSYin Su
Yin Su
LTLi Tang
Li Tang
NONinad Oak
Ninad Oak
KNKim E. Nicols
Kim E. Nicols
Purpose:Pediatric thyroid carcinoma is a rare cancer for which germline genetic factors remain incompletely understood. To gain further insight, we examined the prevalence and spectrum of pathogenic variants (PV) in cancer-predisposing genes (CPG) in a large cohort of children with thyroid carcinoma at our institution.Experimental Design:This retrospective study included 71 children who presented with thyroid carcinoma as a first (n = 52) or subsequent malignant neoplasm (n = 19) and underwent germline testing. The objectives were to determine the proportion of patients harboring PVs and correlate germline information with clinical features, tumor pathology, and outcome.Results:Eighteen patients (25%; 7 primary and 11 subsequent malignant neoplasm) harbored a PV affecting a CPG. Four of these patients had medullary thyroid carcinoma, whereas 14 had nonmedullary thyroid carcinoma. Children diagnosed with thyroid carcinoma before 11 years of age were significantly more likely to harbor PVs (P < 0.01), as were children with medullary histology tumors (P < 0.05) or a prior cancer history (P < 0.001). Both RB1-associated thyroid carcinomas occurred in children who never received prior chemotherapy or radiotherapy. Seventeen patients remain alive at a median of 3 years since diagnosis (1 month–27 years). Twelve of 18 patients with PVs were treated only with thyroidectomy, whereas six required radioactive iodine therapy or chemotherapy. One patient with multiple endocrine neoplasia type 2 expired.Conclusions:A substantial proportion of children with thyroid carcinoma harbor a CPG PV. Accordingly, genetic counseling and testing should be considered for all affected children, especially those who are young, have medullary thyroid carcinoma, or a prior cancer history.